Can a nerve stimulator outsmart a placebo for chronic pain?

NCT ID NCT07779733

First seen Aug 21, 2026 · Last updated Aug 21, 2026

Summary

This trial asks whether continuing BurstDR spinal cord stimulation—a therapy that uses an implanted device to send electrical pulses to the spine—actually relieves chronic pain better than a sham (inactive) stimulation. Adults who already have the device and have experienced good, stable pain relief for at least three months will receive both active and sham stimulation in random order, without knowing which is which. Each person serves as their own comparison, and the study tracks pain levels, satisfaction, sleep, mood, and daily activities to see if the active stimulation truly makes a difference.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
BurstDR spinal cord stimulation (a type of electrical nerve stimulation delivered via an implanted device)
What this could lead to
If active BurstDR proves better than sham, it would confirm that ongoing stimulation is what provides pain relief, supporting its continued use and possibly refining how it's delivered.
What could go wrong
This is a small, early-stage crossover study with only 28 participants. The sham may also provide some relief, and results may not apply to all chronic pain patients. Risks include discomfort or side effects from stimulation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC PAIN are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University Hospital of Northern Sweden

    Umeå, 90185, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.